Results 111 to 120 of about 952,266 (403)

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

Haematologica, 2008
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara, Rossana Maffei, Silvia Martinelli, Annalisa Arcari, Federico Piacentini, Elena Trabacchi, Pierluigi Alfieri, Angela Ferrari, Giovanna Leonardi, Gabriele Luppi, Giuseppe Longo, Daniele Vallisa, Roberto Marasca, Giuseppe Torelli   +13 more
doaj   +1 more source

Biological and technical complexities in analyzing extracellular vesicle immune interactions in B‐cell malignancies

FEBS Letters, EarlyView.
Daniel Bachurski, Michael Hallek
wiley   +1 more source

Current trends in single‐cell RNA sequencing applications in diabetes mellitus

FEBS Open Bio, EarlyView.
Single‐cell RNA sequencing is a powerful approach to decipher the cellular and molecular landscape at a single‐cell resolution. The rapid development of this technology has led to a wide range of applications, including the detection of cellular and molecular mechanisms and the identification and introduction of novel potential diagnostic and ...
Seyed Sajjad Zadian, Khodakaram Jahanbin, Shekoofeh Nikooei, Marzieh Rostaminejad, Arezoo Rahimi, Pedram Abdizadeh, Behnam Alipoor   +6 more
wiley   +1 more source

Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article

مجلة كلية الطب
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram, Fadhel M. Lafta, Bassam F. Matti   +2 more
doaj   +1 more source

Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity

Haematologica, 2008
Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell ...
Désirée Bonci, Maria Musumeci, Valeria Coppola, Antonio Addario, Concetta Conticello, Michael Hahne, Massimo Gulisano, Francesco Grignani, Ruggero De Maria   +8 more
doaj   +1 more source

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]

, 2014
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin, Blatt, Katharina, Cerny-Reiterer, Sabine, Herndlhofer, Susanne, Herrmann, Harald, Hoermann, Grego, Holyoake, Tessa L., Mannhalter, Christine, Mayerhofer, Matthias, Rulicke, Thomas, Sadovnik, Irina, Sperr, Wolfgang R., Stefanzl, Gabriele, Streubel, Berthold, Valent, Peter, Willmann, Michael   +15 more
core   +1 more source

Two‐way inhibition of PAX5 transcriptional activity by PAX5::CBFA2T3

FEBS Open Bio, EarlyView.
PAX5::CBFA2T3 (PAX5‐C) is a fusion protein of the B‐cell transcription factor, PAX5, and is found in B‐cell ALL. We propose a putative model of two‐way inhibition of PAX5 transcriptional activity by PAX5‐C. There are two ways of repression by PAX5‐C: DNA‐binding‐dependent way and HDAC‐dependent way, with either being sufficient for the repression. HDAC
Reina Ueno, Aki Terasaki, Yuiko Imai, Yuri Kimura, Yuna Kojima, Misa Irie, Koya Odaira, Mina Noura, Shuichi Okamoto, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa   +12 more
wiley   +1 more source

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis

Frontiers in Oncology
IntroductionChronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) with ring sideroblasts (RS) or SF3B1 mutation (MDS-RS/SF3B1) differ in many clinical features, but share others, such as anemia.
Blanca Xicoy, Helena Pomares, Mireia Morgades, Ulrich Germing, Montserrat Arnan, Mar Tormo, Laura Palomo, Elisa Orna, Matteo Della Porta, Felicitas Schulz, Marina Díaz-Beya, Ada Esteban, Antonieta Molero, Luca Lanino, Alejandro Avendaño, Francisca Hernández, Verónica Roldan, Marta Ubezio, Alberto Pineda, María Díez-Campelo, Lurdes Zamora   +20 more
doaj   +1 more source

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Haematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Readelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, Rocco Piazza   +27 more
doaj   +1 more source

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors [PDF]

, 2019
In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells (LSCs).
A Hamilton, A Kuma, AS Corbin, B Ronan, B Zhang, B Zhang, BJ Druker, C Bellodi, D Mahalingam, DJ Klionsky, DT Vogl, E Weisberg, F Liu, G Karsli-Uzunbas, JD Mancias, JY Guo, JY Guo, M Karvela, M Komatsu, M Mortensen, M Schemionek, MR Rosenfeld, MR Warr, MT Rosenfeldt, N Mizushima, P Rousselot, Q McAfee, R Bago, R Rangwala, R Rangwala, S Brenner, S Kimura, S Koschmieder, SM Graham, T Holyoake, TL Holyoake, TL Holyoake, TT Ho, V Kirkin, VW Rebecca, WE Dowdle, XH Ma, Z Tothova   +42 more
core   +2 more sources